Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review
IntroductionThis scoping review explores the effectiveness of IL-1 pathway inhibitors in managing PSTPIP1-associated inflammatory diseases (PAID). These diseases are marked by abnormal IL-1 pathway activation due to genetic mutations.MethodsOur methodology adhered to a pre-published protocol and inv...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1339337/full |
| _version_ | 1797360335880978432 |
|---|---|
| author | Juan Luis Sanz-Cabanillas Juan Luis Sanz-Cabanillas Francisco Gómez-García Francisco Gómez-García Pedro Jesús Gómez-Arias Pedro Jesús Gómez-Arias Ana Montilla-López Jesús Gay-Mimbrera Juan Ruano Juan Ruano Juan Ruano Beatriz Isla-Tejera Beatriz Isla-Tejera Esmeralda Parra-Peralbo |
| author_facet | Juan Luis Sanz-Cabanillas Juan Luis Sanz-Cabanillas Francisco Gómez-García Francisco Gómez-García Pedro Jesús Gómez-Arias Pedro Jesús Gómez-Arias Ana Montilla-López Jesús Gay-Mimbrera Juan Ruano Juan Ruano Juan Ruano Beatriz Isla-Tejera Beatriz Isla-Tejera Esmeralda Parra-Peralbo |
| author_sort | Juan Luis Sanz-Cabanillas |
| collection | DOAJ |
| description | IntroductionThis scoping review explores the effectiveness of IL-1 pathway inhibitors in managing PSTPIP1-associated inflammatory diseases (PAID). These diseases are marked by abnormal IL-1 pathway activation due to genetic mutations.MethodsOur methodology adhered to a pre-published protocol and involved a thorough search of MEDLINE and EMBASE databases up to February 2022, following the Joanna Briggs Institute Reviewer’s Manual and the PRISMA Extension for Scoping Reviews. The review included studies reporting on IL-1 pathway inhibitor use in PAID patients.ResultsFrom an initial pool of 5,225 articles, 36 studies involving 43 patients were selected. The studies predominantly used observational designs and exhibited diversity in patient demographics, treatment approaches, and outcomes. Anakinra and canakinumab demonstrated promise in treating sterile pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) and PSTPIP1-associated myeloid-related-proteinemia inflammatory (PAMI) syndromes, with scant data on other syndromes. Notably, there was a paucity of information on the adverse effects of these treatments, necessitating cautious interpretation of their safety profile.ConclusionCurrent evidence on IL-1 pathway inhibitors for PAID is primarily from observational studies and remains limited. Rigorous research with larger patient cohorts is imperative for more definitive conclusions. Collaborative efforts among specialized research centers and international health initiatives are key to advancing this field. |
| first_indexed | 2024-03-08T15:38:05Z |
| format | Article |
| id | doaj.art-bdaffb302326414e9a5c10d7da31ef1c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T15:38:05Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-bdaffb302326414e9a5c10d7da31ef1c2024-01-09T17:47:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-01-011410.3389/fimmu.2023.13393371339337Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping reviewJuan Luis Sanz-Cabanillas0Juan Luis Sanz-Cabanillas1Francisco Gómez-García2Francisco Gómez-García3Pedro Jesús Gómez-Arias4Pedro Jesús Gómez-Arias5Ana Montilla-López6Jesús Gay-Mimbrera7Juan Ruano8Juan Ruano9Juan Ruano10Beatriz Isla-Tejera11Beatriz Isla-Tejera12Esmeralda Parra-Peralbo13Inflammatory Immune-mediated Chronic Skin Diseases’ Laboratory, IMIBIC/Reina Sofia University Hospital/University of Cordoba, Córdoba, SpainDepartment of Dermatology, Reina Sofia University Hospital, Córdoba, SpainInflammatory Immune-mediated Chronic Skin Diseases’ Laboratory, IMIBIC/Reina Sofia University Hospital/University of Cordoba, Córdoba, SpainDepartment of Dermatology, Reina Sofia University Hospital, Córdoba, SpainInflammatory Immune-mediated Chronic Skin Diseases’ Laboratory, IMIBIC/Reina Sofia University Hospital/University of Cordoba, Córdoba, SpainDepartment of Dermatology, Reina Sofia University Hospital, Córdoba, SpainInflammatory Immune-mediated Chronic Skin Diseases’ Laboratory, IMIBIC/Reina Sofia University Hospital/University of Cordoba, Córdoba, SpainInflammatory Immune-mediated Chronic Skin Diseases’ Laboratory, IMIBIC/Reina Sofia University Hospital/University of Cordoba, Córdoba, SpainInflammatory Immune-mediated Chronic Skin Diseases’ Laboratory, IMIBIC/Reina Sofia University Hospital/University of Cordoba, Córdoba, SpainDepartment of Dermatology, Reina Sofia University Hospital, Córdoba, SpainSchool of Medicine and Nursing, University of Cordoba, Córdoba, SpainInflammatory Immune-mediated Chronic Skin Diseases’ Laboratory, IMIBIC/Reina Sofia University Hospital/University of Cordoba, Córdoba, SpainDepartment of Pharmacology, Reina Sofia University Hospital, Córdoba, SpainDepartment of Pharmacy and Nutrition, Faculty of Biomedical Science and Health, Universidad Europea, Madrid, SpainIntroductionThis scoping review explores the effectiveness of IL-1 pathway inhibitors in managing PSTPIP1-associated inflammatory diseases (PAID). These diseases are marked by abnormal IL-1 pathway activation due to genetic mutations.MethodsOur methodology adhered to a pre-published protocol and involved a thorough search of MEDLINE and EMBASE databases up to February 2022, following the Joanna Briggs Institute Reviewer’s Manual and the PRISMA Extension for Scoping Reviews. The review included studies reporting on IL-1 pathway inhibitor use in PAID patients.ResultsFrom an initial pool of 5,225 articles, 36 studies involving 43 patients were selected. The studies predominantly used observational designs and exhibited diversity in patient demographics, treatment approaches, and outcomes. Anakinra and canakinumab demonstrated promise in treating sterile pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) and PSTPIP1-associated myeloid-related-proteinemia inflammatory (PAMI) syndromes, with scant data on other syndromes. Notably, there was a paucity of information on the adverse effects of these treatments, necessitating cautious interpretation of their safety profile.ConclusionCurrent evidence on IL-1 pathway inhibitors for PAID is primarily from observational studies and remains limited. Rigorous research with larger patient cohorts is imperative for more definitive conclusions. Collaborative efforts among specialized research centers and international health initiatives are key to advancing this field.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1339337/fullautoinflammatory diseasesPSTPIP1 gene mutationsPAIDinterleukin 1 pathwayIL-1 inhibitorsanakinra |
| spellingShingle | Juan Luis Sanz-Cabanillas Juan Luis Sanz-Cabanillas Francisco Gómez-García Francisco Gómez-García Pedro Jesús Gómez-Arias Pedro Jesús Gómez-Arias Ana Montilla-López Jesús Gay-Mimbrera Juan Ruano Juan Ruano Juan Ruano Beatriz Isla-Tejera Beatriz Isla-Tejera Esmeralda Parra-Peralbo Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review Frontiers in Immunology autoinflammatory diseases PSTPIP1 gene mutations PAID interleukin 1 pathway IL-1 inhibitors anakinra |
| title | Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review |
| title_full | Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review |
| title_fullStr | Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review |
| title_full_unstemmed | Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review |
| title_short | Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review |
| title_sort | efficacy and safety of anakinra and canakinumab in pstpip1 associated inflammatory diseases a comprehensive scoping review |
| topic | autoinflammatory diseases PSTPIP1 gene mutations PAID interleukin 1 pathway IL-1 inhibitors anakinra |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1339337/full |
| work_keys_str_mv | AT juanluissanzcabanillas efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT juanluissanzcabanillas efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT franciscogomezgarcia efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT franciscogomezgarcia efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT pedrojesusgomezarias efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT pedrojesusgomezarias efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT anamontillalopez efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT jesusgaymimbrera efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT juanruano efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT juanruano efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT juanruano efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT beatrizislatejera efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT beatrizislatejera efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview AT esmeraldaparraperalbo efficacyandsafetyofanakinraandcanakinumabinpstpip1associatedinflammatorydiseasesacomprehensivescopingreview |